Cleveland BioLabs reported a net loss for the third quarter of 2014 of $4.1 million, or $0.07 per share, compared to a net loss of $4.1 million, or $0.09 per share, for the same period in 2013. Net loss for the first nine months of 2014 was $9.6 million, or $0.18 per share, compared to a net loss of $16.9 million, or $0.38 per share, for the same period in 2013, a reduction of $7.3 million. This net loss reduction was due to a reduction in operating losses of $9.1 million, and $1.2 million of non-cash income related to a change in value of accrued warrant liability, offset by $1.2 million for additional interest expense, $0.4 million in foreign exchange losses and $1.4 million in losses attributed to minority interests. The reduced operating losses were due to a narrowed focus of development activities, lower development costs for entolimod's biodefense indication and other cost saving measures.

At September 30, 2014, the Company had cash, cash equivalents and short-term investments of $9.1 million, $4.9 million of which was available for general use and $4.2 million of which was restricted for the use of subsidiaries.

Yakov Kogan, Ph.D., MBA, Chief Executive Officer, stated, "We achieved several milestones during the third quarter. Agreement was reached with the U.S. Food and Drug Administration that our existing efficacy and safety data and animal-to-human dose conversion are sufficient to proceed with a pre-Emergency Use Authorization (pre-EUA) submission for entolimod's biodefense indication. Our team has been focused on compiling an application that has the highest chances for success as quickly as possible. On the oncology side of our business, the Phase 1 study of entolimod in patients with advanced cancer at Roswell Park Cancer Institute has been concluded. Analysis of trial data, including immune cell response, is expected to be complete in the first half of 2015. We are preparing a small expansion study in the Russian Federation to gather additional immune cell response data at the highest dose levels reached in the Roswell Park study. This expansion study will be financially supported by a matching-funds grant from the Russian Ministry of Industry and Trade. We are also finalizing interim data for the oral administration study of Curaxin CBL0137. Lastly, dosing was started in a Phase 1 healthy subject study of CBLB612, a drug candidate in development for the induction and mobilization of hematopoietic stem cells (HSCs). In addition to evaluating safety, tolerability and pharmacology of a single administration of CBLB612, this study has been designed to characterize the type, quantity and timing of HSC mobilization in these subjects."

Recruitment of the sixth cohort is underway in a multi-center, Phase 1 trial assessing the intravenous administration of Curaxin CBL0137 in patients with metastatic or unresectable advanced solid cancers and lymphomas. In parallel, dosing of the eighth cohort is ongoing in a multicenter, Phase 1 study assessing the oral administration of Curaxin CBL0137 in patients with advanced solid tumors that are resistant or refractory to current standard treatment. To date, no drug-related serious adverse events have been reported in either trial.

Further Financial Highlights

Revenue for the third quarter of 2014 decreased to $0.4 million compared to $1.6 million for the third quarter of 2013. Revenue for the first nine months of 2014 decreased to $2.3 million compared to $4.6 million for the same period in 2013. These decreases were primarily the result of the completion of contracts with the Department of Defense for entolimod's biodefense indication and variances in the levels of development activity under other contracts with the Ministry of Industry and Trade of the Russian Federation, or MPT.

Research and development costs for the third quarter of 2014 decreased to $2.1 million compared to $4.2 million for the same period in 2013. Nine-month research and development costs for the 2014 period decreased to $6.8 million compared to $14.9 million for the same period in 2013. These decreases were primarily due to completion of third-party service contracts for several compounds in-line with and largely in support of the contracted development work discussed above, as well as reduced compensation costs primarily attributable to our transfer of personnel to Buffalo BioLabs, LLC in the fourth quarter of 2013.

General and administrative costs for the third quarter of 2014 decreased to $1.8 million compared to $3.3 million for the same period in 2013. General and administrative costs for the first nine months of 2014 decreased to $6.5 million compared to $9.8 million for the same period in 2013. For the nine-month period, $2.0 million of these decreases were due to reduction in costs related to our personnel and consultants and $1.3 million were due to other cost-saving actions.

Conference Call InformationCleveland BioLabs management will host a conference call at 10:00 a.m. ET today to provide updates and address investor questions regarding general business developments. Interested parties may participate by dialing 877-407-9205 (US) or 201-689-8054 (International), approximately five to ten minutes before the call start time. A live webcast of the conference call will be available on the investor page of the Cleveland BioLabs web site at www.cbiolabs.com. A replay of the call will be available starting on November 5, 2014, at 1:00 p.m. ET through November 19, 2014, at 11:59 p.m. ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering conference ID number 13593933. An archived webcast of the conference call will be available for 90 days on the Investors page of the Cleveland BioLabs web site at www.cbiolabs.com.

About Cleveland BioLabs Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are entolimod, which is being developed for a biodefense indication and as a potential cancer treatment, and Curaxin CBL0137, our lead oncology product candidate. The company conducts business in the United States and in the Russian Federation through our three operating subsidiaries, Incuron, LLC, BioLabs 612, LLC and Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children's Cancer Institute Australia. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.

This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "preparing," "finalizing," and "underway" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our therapeutic products; our ability to successfully submit and receive approval of our pre-EUA application for entolimod, the conduct and results of our various clinical trials; our ability to obtain approval from the U.S. Food and Drug Administration of our product candidates; our ability to successfully submit and receive approval of our pre-EUA application for entolimod; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

These risks and uncertainties include, among others, the Company's failure to successfully and timely develop existing and new products; the Company's collaborative relationships and the financial risks related thereto; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company's ability to comply with its obligations under license agreements; the Company's inability to obtain regulatory approval in a timely manner or at all; subsequent changes in the agreement with the Russian Ministry of Industry and Trade, the Company's history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.

TABLES FOLLOW

CLEVELAND BIOLABS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

September 30,

December 31,

2014

2013

(unaudited)

ASSETS

Current assets:

Cash and cash equivalents

$

7,877,432

$

10,048,466

Short-term investments

1,269,467

305,538

Accounts receivable

175,191

458,391

Other current assets

365,461

344,386

Total current assets

9,687,551

11,156,781

Equipment, net

287,827

457,912

Restricted cash

2,427,874

2,921,724

Other long-term assets

65,192

159,224

Total assets

$

12,468,444

$

14,695,641

LIABILITIES & STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable

$

889,402

$

794,397

Accrued expenses

1,796,382

2,445,446

Deferred revenue

356,580

1,069,438

Accrued warrant liability

1,861,013

1,241,311

Current portion of note payable

735,654

351,527

Current portion of capital lease obligation

29,560

83,634

5,668,591

5,985,753

Noncurrent portion of capital lease obligation

-

7,522

Long-term debt

3,479,396

7,121,388

Commitments and contingencies

-

-

Total liabilities

9,147,987

13,114,663

Stockholders' equity:

Total Cleveland BioLabs, Inc. stockholders' deficit

(10,349,558

)

(9,522,945

)

Noncontrolling interest in stockholders' equity

13,670,015

11,103,923

Total stockholders' equity

3,320,457

1,580,978

Total liabilities and stockholders' equity

$

12,468,444

$

14,695,641

CLEVELAND BIOLABS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

Quarter Ended
September 30,

Nine months ended
September 30,

2014

2013

2014

2013

Revenues:

Grants and contracts

$

415,126

$

1,635,600

$

2,311,467

$

4,616,334

Operating expenses:

Research and development

2,068,245

4,205,238

6,832,241

14,909,882

General and administrative

1,785,620

3,286,830

6,449,531

9,787,053

Total operating expenses

3,853,865

7,492,068

13,281,772

24,696,935

Loss from operations

(3,438,739

)

(5,856,468

)

(10,970,305

)

(20,080,601

)

Other income (expense):

Interest and other income (expense)

(68,932

)

97,534

(1,010,640

)

225,299

Foreign exchange gain (loss)

(271,699

)

(15,057

)

(330,876

)

59,853

Change in value of warrant liability

(836,293

)

1,163,030

1,663,390

510,919

Total other income (expense)

(1,176,924

)

1,245,507

321,874

796,071

Net loss

(4,615,663

)

(4,610,961

)

(10,648,431

)

(19,284,530

)

Net loss attributable to noncontrolling interests

519,529

519,765

1,005,764

2,386,900

Net loss attributable to Cleveland BioLabs, Inc.

$

(4,096,134

)

$

(4,091,196

)

$

(9,642,667

)

$

(16,897,630

)

Net loss available to common stockholders per share of common stock, basic and diluted

$

(0.07

)

$

(0.09

)

$

(0.18

)

$

(0.38

)

Weighted average number of shares used in calculating net loss per share, basic and diluted

57,110,198

45,061,274

53,016,147

44,946,340

CLEVELAND BIOLABS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Nine Months Ended September 30,

2014

2013

Cash flows used in operating activities

$

(11,316,565

)

$

(18,923,142

)

Cash flows provided by (used in) investing activities

(1,142,661

)

666,920

Cash flows provided by financing activities

10,788,298

7,251,055

Effect of exchange rate change on cash and equivalents

(500,106

)

(333,995

)

Increase (decrease) in cash and cash equivalents

(2,171,034

)

(11,339,162

)

Cash and cash equivalents at beginning of period

10,048,466

25,652,083

Cash and cash equivalents at end of period

$

7,877,432

$

14,312,921

CLEVELAND BIOLABS, INC. AND SUBSIDIARIES

NON-GAAP FINANCIAL MEASURES

(UNAUDITED)

We define net cash burn as the net increase (or decrease) in cash, cash equivalents and short-term investments excluding the effect of capital markets financing activities, and the net increase (or decrease) in restricted cash, as determined in accordance with generally accepted accounting principles or GAAP. And we separately track net cash burn for Cleveland BioLabs, Inc. and its wholly-owned subsidiary BioLab 612, LLC, which we refer to as CBLI Stand-alone, as well as for the consolidated entity which includes the accounts of Incuron, LLC, Panacela Labs, Inc. and Panacela Labs, LLC. This non-GAAP measure may be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. We believe that net cash burn is relevant and useful information for the Company and our investors as it provides a simple method of determining net cash used by the Company. A calculation of net cash burn is provided below:

Quarter Ended
September 30,

Nine months ended
September 30,

2014

2013

2014

2013

CBLI Stand-alone:

Cash, cash equivalents, and short-term investments, beginning of period

$

7,654,233

$

8,789,689

$

7,957,302

$

17,945,147

Cash, cash equivalents and short-term investments, end of period

4,881,603

10,831,221

4,881,603

10,831,221

Period increase/(decrease)

(2,772,630

)

2,041,532

(3,075,699

)

(7,113,926

)

Less net proceeds from the sale of common stock

-

-

(9,697,501

)

-

Plus/(minus) loan prepayments/(proceeds)

-

(5,797,675

)

4,000,000

(5,797,675

)

Net cash burn for the period

(2,772,630

)

(3,756,143

)

(8,773,200

)

(12,911,601

)

Number of months in period

3

3

9

9

Net monthly cash burn

$

(924,210

)

$

(1,252,048

)

$

(974,800

)

$

(1,434,622

)

Consolidated:

Cash, cash equivalents, and short-term investments, beginning of period